Startseite>>Proteins>> Enzymes>> Phosphatase>>IACS-13909

IACS-13909

Katalog-Nr.GC62345

IACS-13909 ist ein selektiver, potenter und oral wirksamer allosterischer SHP2-Inhibitor mit einem IC50 von 15,7 nM und einem Kd von 32 nM. IACS-13909 ist selektiver fÜr SHP2 als andere Phosphatasen (einschließlich SHP1). IACS-13909 hat AntitumoraktivitÄten und unterdrÜckt die SignalÜbertragung des MAPK-Wegs bei Rezeptortyrosinkinasen (RTK)-abhÄngigen Krebsarten.

Products are for research use only. Not for human use. We do not sell to patients.

IACS-13909 Chemische Struktur

Cas No.: 2160546-07-4

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
223,00 $
Auf Lager
1mg
81,00 $
Auf Lager
5mg
203,00 $
Auf Lager
10mg
322,00 $
Auf Lager
25mg
644,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

IACS-13909 is a selective, potent and orally active SHP2 allosteric inhibitor with an IC50 of 15.7 nM and a Kd of 32 nM. IACS-13909 is more selective for SHP2 than other phosphatases (including SHP1). IACS-13909 has antitumor activities and suppresses MAPK pathway signaling in receptor tyrosine kinases (RTK)-dependent cancers[1].

IACS-13909 (10 nM-10 μM; 14 days) treatment potently suppresses the proliferation of wild-type SHP2 and KYSE-520 cells[1].IACS-13909 (1-5 μM; 2 hours) treatment potently suppresses pERK and pMEK levels in wild-type SHP2 and KYSE-520 cells[1].IACS-13909 potently suppresses the proliferation of both the parental cells and NCI-H1975 CS cells in a dose-dependent manner, with similar potency (GI50 ~1 μM). IACS-13909 (0.041-3.3 μM) suppresses pERK in NCI-H1975 CS cells in a dose-dependent manner[1].

IACS-13909 (70 mg/kg; oral administration; daily; for 21 days) treatment potently suppresses tumor growth in mice, with 100% tumor growth inhibition (TGI) observed following 21 days of dosing[1].

[1]. Yuting Sun, et al. Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib. Cancer Res. 2020 Nov 1;80(21):4840-4853.

Bewertungen

Review for IACS-13909

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for IACS-13909

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.